A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

Summary

This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \[18F\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission. The overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission/synthesis capacity in the striatum and midbrain as measured by \[18F\]DOPA Kicer (\[18F\]DOPA relative uptake rate)).

Timeline

Start

2026-07-01

Primary completion

2027-04-30

Completion

2027-12-31

Drugs

Indications